Introduction {#sec1}
============

Long lasting living has been a desire and a target for human beings \[[@cit0001]\]. During the last 2 decades, several research groups have been vigorously evaluating various single nucleotide polymorphisms (SNPs) involved in human ageing or exceptional longevity \[[@cit0002]--[@cit0004]\]. Consequently, many studies evaluating the frequency of particular gene polymorphisms in ageing have already been published, with inconsistent results. The main reasons for these conflicting results are the differences in nationality, gender and environmental status of the evaluated cohorts. Furthermore, it is possible that, apart from environmental factors, every nation may have favorable and non-favorable combinations of gene polymorphisms, leading to longer or shorter lifespan. Moreover, it is believed that genetic influence is more profound after the age of 85 years \[[@cit0002]\].

To inhibit the loss of coding sequences and suppress the chromosomal reorganizations, linear chromosomes are capped by repetitive nucleoprotein structures, named telomeres. Every cell splitting results in a gradual reduction of telomere length that, below a certain shortening, evokes genome instability, senescence and apoptosis. Telomerase, a ribonucleic protein that consists of a telomere reverse transcriptase (TERT, catalytic subunit) and a telomere RNA component, is the main regulator of telomere length \[[@cit0004], [@cit0005]\]. The *TERT* gene encodes the catalytic subunit of telomerase. In the present study, in line with a previous one \[[@cit0003]\], we investigated gene variants that could explain the extended lifespan of nonagenarians and centenarians compared with middle-aged individuals in the Greek population. In this context, we evaluated the *TERT* gene polymorphism rs2736098, located on chromosome 5 at position NM_001193376.1: c.915G\>A, that appears to associate with cancer diseases (one of the major causes of shortened lifespan).

Insulin-like growth factor-1 (IGF-1) was negatively correlated with age \[[@cit0006]\]. Circulating insulin-like growth factor-1 binding protein-3 (IGFBP-3) is bound to about 90% of the circulating IGF-1 that exerts mitogenic and metabolic activities in the regulation of growth, survival and cell differentiation \[[@cit0007]\]. *IGFBP3* (*A-202C*, rs2854744) gene polymorphism, located on chromosome 7 at position NM_000598.4: c.-336C\>A, was found to be significantly associated with circulating IGFBP-3 levels. There is some evidence that the alleles associated with higher circulating IGFBP-3 levels are also associated with higher risk of early stage of cancers \[[@cit0008]\].

Genetic variations in transcription factor Fork-head box O3A (*FOXO3A*) have been associated with human longevity in nations such as the Japanese, Chinese, Italian and German \[[@cit0009]--[@cit0012]\]. *FOXO3A* forms part of the IGF-1 signaling pathway. In the present study, we evaluated two SNPs of the *FOXO3A* gene (rs13217795 located on chromosome 6 at position NM_01455.3: c.622-10560C\>T and rs2764264 located on chromosome 6 at position NM_001455.3: c.622-50197C\>T). The IGF-1 pathway highly interacts with the p53 pathway, a nuclear protein involved in several signaling pathways, including DNA damage recognition, cell cycle control and meiotic recombination (important components involved in longevity) \[[@cit0013]\].

Adiponectin, an adipose tissue-derived peptide, is a determinant of insulin sensitivity that exerts anti-inflammatory and anti-atherogenic effects. Decreased plasma adiponectin levels are associated with type 2 diabetes mellitus and atherosclerosis (both diseases can shorten the lifespan). The adiponectin-encoding gene (*ADIPOQ*) is located on chromosome 3 and the SNP which we evaluated (*ADIPOQ* +45T\>G) is at position NM_004797.3: c.45T\>G \[[@cit0014]\].

We made the hypothesis that gene polymorphisms involved either in cell instability, senescence, and apoptosis or determining the risk of diseases development leading to lifespan shortening (cancer, diabetes mellitus, coronary heart disease (CHD)) will present with different frequencies according to age.

The aim of the present study was to evaluate whether there is any difference in the frequency of common gene polymorphisms (i.e. TERT, IGFBP3, FOXO3A and ADIPOQ) between nonagenarians and centenarians (study group) and middle-aged individuals (control group).

Material and methods {#sec2}
====================

The present study was designed and performed in agreement with the recommendations for the human genotype-phenotype association studies published by the National Cancer Institute-National Human Genome Research Institute (NCI-NHGRI) Working Group on Replication in Association Studies \[[@cit0015]\] indicating the time period and location of subject recruitment, success rate for DNA acquisition, internal control samples (from the same DNA) and sample tracking methods.

The study protocol was approved by the Institutional Ethics Committee (Onassis Cardiac Surgery Center, Athens, Greece) and was in accordance with the Declaration of Helsinki for Human Research of 1974 (last modified in 2000) \[[@cit0016]\]. All study participants were of Caucasian origin and descent for ≥ 3 generations.

Control group (*n* = 149). The inclusion criteria were: 1. age 18 -- \< 80 years, and 2. no personal history of CHD, diabetes mellitus, thyroid or liver disease, high alcohol consumption, professional athleticism and any chronic disease.

Study group with nonagenarians and centenarians (*n* = 256). The inclusion criteria were age 90--99 years in nonagenarians and \> 99 years in centenarians. No other inclusion or exclusion criteria were applied.

Genotyping {#sec2.1}
----------

Genotyping was performed specifically for research purposes. Extraction of genomic DNA was performed from leukocytes separated from whole blood using a standard method with the FlexiGene DNA kit (Qiagen).

The study variants were detected using polymerase chain reaction (PCR) and restricted fragment length polymorphism analysis (RFLPs). The PCR was performed using KAPA TaqDNA polymerase (KAPA Biosystems). The oligonucleotide primers, the PCR conditions and the restriction enzymes for each SNP are listed in [Table I](#t0001){ref-type="table"}. All samples were subjected to electrophoresis on an agarose gel 3% and visualized with ethidium bromide.

###### 

Genotyping methodology

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         SNP         Name                           Primer sequences (5ʹ→3ʹ)         Ref.                           T~m~ \[°C\]   PCR product \[bp\]   Restriction enzyme   After digestion
  ------------ ----------- ------------------------------ -------------------------------- ------------------------------ ------------- -------------------- -------------------- -------------------
  *TERT*       rs2736098   p.Ala305Ala                    F: ACCGTGGTTTCTGTGTGGTGTCA\      --                             60            207                  PspOM I              116 bp and 91 bp
                                                          R: CTGAGGAGTAGAGGAAGTGC                                                                                                 

  *FOXO3A*     rs2764264   --                             F: AGGATTTTTGTGTCTGTCTTCACG\     --                             55            202                  NlaIII               101 bp and 101 bp
                                                          R: ACTCCAGGCTCTGATGGCTTAACT                                                                                             

  rs13217795   --          F: GGCCCTGGTAGGCACCACATACAT\   --                               64                             284           BspHI                193 bp and 91 bp     
                           R: ACTGATAGGGTGTGTGCTACTCGG                                                                                                                            

  *ADIPOQ*     rs2241766   c.+45T\>G                      F: GCAGCTCCTAGAAGTAGACTCTGCTG\   Guzman-Ornelas\                68            372                  BspHI                206 bp and 166 bp
                                                          R: GGAGGTCTGTGATGAAAGAGGCC       *et al.* \[[@cit0023]\]                                                                

  *IGFBP3*     rs2854744   A-202C or\                     F: CCACGAGGTACACACGAATG\         Deal *et al.* \[[@cit0031]\]   58            463                  FspI                 241 bp and 222 bp
                           c.-336C\>A                     R: AGCCGCAGTGCTCGCATCTGG                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The RFLP results were validated by: 1) around 20% of all samples were repeated to confirm findings of the PCR-RFLP method and 2) randomly selected PCR-RFLP results were confirmed by direct automated sequencing of PCR products for each polymorphism using the BigDye terminator chemistry kit (ABI, USA) and 3500 genetic analyzer (ABI, USA). The concordance between repeated samples, sequencing and our results was 100%.

Statistical analysis {#sec2.2}
--------------------

All categorical variables are described as absolute (*N*) and relative (%) frequencies. Potential associations between the study variables were tested using Pearson's c^2^ test or Fisher's exact test, when appropriate. All tests were two-sided and were considered significant if the *p*-value was \< 0.05. Data were analyzed using IBM SPSS statistical software version 22.0 for Windows (IBM Corporation, NY, USA).

Results {#sec3}
=======

The age of the study group ranged between 90 and 113 years (median ± interquartile range (IQR): 93 ±4 years). Overall, 17 individuals were centenarians (from 100 to 113 years, 101 ±5 years). The corresponding age of the control group was 56 ± 27 years, ranging from 18 to 80 years. The frequency of women was significantly higher in the study group than the control group (64.5 vs. 49.7%, *p* = 0.004) ([Table II](#t0002){ref-type="table"}).

###### 

Genotype frequencies between the study group and the control group

  Variable                                                All   Control group   Study group   *P*-value                
  ------------------------------------------------------- ----- --------------- ------------- ----------- ----- ------ -------
  Gender:                                                                                                              
   Male                                                   166   41.0            75            50.3        91    35.5   0.004
   Female                                                 239   59.0            74            49.7        165   64.5   
  Genotypes:                                                                                                           
   *TERT* rs2736098[\*](#tf2-1){ref-type="table-fn"}                                                                   
   AA                                                     31    8.2             8             6.3         23    8.9    0.685
   AG                                                     154   40.4            52            40.6        103   40.2   
   GG                                                     196   51.4            68            53.1        130   50.5   
   *IGFBP3* rs2854744[\*](#tf2-1){ref-type="table-fn"}:                                                                
   AA                                                     106   28.4            29            24.4        77    30.3   0.392
   AC                                                     188   50.4            61            51.3        127   50.0   
   CC                                                     79    21.2            29            24.4        50    19.7   
   *FOXO3A* rs13217795:                                                                                                
   CC                                                     55    13.6            22            14.9        33    12.9   0.837
   CT                                                     191   47.3            68            45.9        123   48.0   
   TT                                                     158   39.1            58            39.2        100   39.1   
   *FOXO3A* rs2764264:                                                                                                 
   TT                                                     158   39.1            54            36.5        104   40.6   0.070
   TC                                                     222   55.0            80            54.1        142   55.5   
   CC                                                     24    5.9             14            9.5         10    3.9    
   *ADIPOQ* rs2241766:                                                                                                 
   TT                                                     276   68.7            100           67.6        176   69.0   0.124
   TG                                                     115   28.6            47            31.7        70    27.1   
   GG                                                     11    2.7             1             0.7         10    3.9    

20 genotype analyses were missing in the control group.

Genetic gender difference {#sec3.1}
-------------------------

Genotypic ([Tables III](#t0003){ref-type="table"}--[VI](#t0006){ref-type="table"}) and allele frequencies (not shown) did not differ by gender in either of the 2 groups. However, in men, the frequency of *TT* genotype of *FOXO3A*; rs2764264 was higher in the study group than the control group (45.6 vs. 28.0%, *p* = 0.050) ([Table III](#t0003){ref-type="table"}).

###### 

Genotype frequencies in men

  Variable                Control group   Study group   *P*-value           
  ----------------------- --------------- ------------- ----------- ------- -------
  Gender:                                                                   
   Male                   75              100.0         91          100.0   
   Female                 0               0.0           0           0.0     
  Genotypes:                                                                
   *TERT* rs2736098:                                                        
   AA                     7               11.1          8           8.8     0.890
   GA                     26              41.3          38          41.8    
   GG                     30              47.6          45          49.5    
   *IGFBP3* rs2854744:                                                      
   AA                     16              27.1          27          30.7    0.785
   AC                     29              49.2          44          50.0    
   CC                     14              23.7          17          19.3    
   *FOXO3A* rs13217795:                                                     
   CC                     12              16.2          14          15.6    0.413
   CT                     38              51.4          38          42.2    
   TT                     24              32.4          38          42.2    
   *FOXO3A* rs2764264:                                                      
   TT                     21              28.0          41          45.6    0.050
   CT                     47              62.7          45          50.0    
   CC                     7               9.3           4           4.4     
   *ADIPOQ* rs2241766:                                                      
   TT                     46              61.3          61          67.8    0.291
   TG                     28              37.3          25          27.8    
   GG                     1               1.3           4           4.4     

###### 

Genotype frequencies in women

  Variable                Control group   Study group   *P*-value           
  ----------------------- --------------- ------------- ----------- ------- -------
  Gender:                                                                   
  * *Male                 0               0.0           0           0.0     
  * *Female               74              100.0         165         100.0   
  Genotypes:                                                                
  * TERT* rs2736098:                                                        
   AA                     1               1.6           15          9.1     0.132
   GA                     24              39.3          66          40.0    
   GG                     36              59.0          84          50.9    
  * IGFBP3* rs2854744:                                                      
   AA                     13              21.7          50          30.3    0.384
   AC                     32              53.3          83          50.3    
   CC                     15              25.0          32          19.4    
  * FOXO3A* rs13217795:                                                     
   CC                     10              13.5          19          11.5    0.331
   CT                     30              40.5          84          50.9    
   TT                     34              45.9          62          37.6    
  * FOXO3A* rs2764264:                                                      
   TT                     33              45.2          63          38.2    0.065
   CT                     33              45.2          96          58.2    
   CC                     7               9.6           6           3.6     
  * ADIPOQ* rs2241766:                                                      
   TT                     54              75.0          114         69.5    0.283
   TG                     18              25.0          44          26.8    
   GG                     0               0.0           6           3.7     

###### 

Genotype frequencies in the control group according to gender

  Genotypes              Control group   *P*-value               
  ---------------------- --------------- ----------- ---- ------ -------
  *TERT* rs2736098:                                              
   AA                    7               11.1        1    1.6    0.085
   GA                    26              41.3        24   39.3   
   GG                    30              47.6        36   59.0   
  *IGFBP3* rs2854744:                                            
   AA                    16              27.1        13   21.7   0.785
   AC                    29              49.2        32   53.3   
   CC                    14              23.7        15   25.0   
  *FOXO3A* rs13217795:                                           
   CC                    12              16.2        10   13.5   0.241
   CT                    38              51.4        30   40.5   
   TT                    24              32.4        34   45.9   
  *FOXO3A* rs2764264:                                            
   TT                    21              28.0        33   45.2   0.078
   CT                    47              62.7        33   45.2   
   CC                    7               9.3         7    9.6    
  *ADIPOQ* rs2241766:                                            
   TT                    46              61.3        54   75.0   0.111
   TG                    28              37.3        18   25.0   
   GG                    1               1.3         0    0.0    

###### 

Genotype frequencies in the study group according to gender

  Genotypes              Study group   *P*-value                
  ---------------------- ------------- ----------- ----- ------ -------
  *TERT* rs2736098:                                             
   AA                    8             8.8         15    9.1    0.963
   GA                    38            41.8        66    40.0   
   GG                    45            49.5        84    50.9   
  *IGFBP3* rs2854744:                                           
   AA                    27            30.7        50    30.3   0.998
   AC                    44            50.0        83    50.3   
   CC                    17            19.3        32    19.4   
  *FOXO3A* rs13217795:                                          
   CC                    14            15.6        19    11.5   0.373
   CT                    38            42.2        84    50.9   
   TT                    38            42.2        62    37.6   
  *FOXO3A* rs2764264:                                           
   TT                    41            45.6        63    38.2   0.454
   CT                    45            50.0        96    58.2   
   CC                    4             4.4         6     3.6    
  *ADIPOQ* rs2241766:                                           
   TT                    61            67.8        114   69.5   0.934
   TG                    25            27.8        44    26.8   
   GG                    4             4.4         6     3.7    

Gene distribution in the study group and control group {#sec3.2}
------------------------------------------------------

No significant difference was found in the distribution of all genotypes between the 2 groups ([Table II](#t0002){ref-type="table"}). When the evaluation was referred to the alleles, the relative frequency of the *C* allele (*FOXO3A*, rs2764264) was significantly lower in the study group than the control group (3.9 vs. 9.5%, *p* = 0.023) ([Table VII](#t0007){ref-type="table"}).

###### 

Allele frequencies among the 2 studied groups (in both genders)

  Alleles                Control group   Study group                
  ---------------------- --------------- ------------- ----- ------ -------
  *TERT* rs2736095:                                                 
   A                     58              46.8          127   49.4   0.629
   G                     66              53.2          130   50.6   
  *IGFBP3* rs2854744:                                               
   A                     90              75.6          204   80.3   0.302
   C                     29              24.4          50    19.7   
  *FOXO3A* rs13217795:                                              
   C                     90              60.8          156   60.9   0.980
   T                     58              39.2          100   39.1   
  *FOXO3A* rs2764264:                                               
   T                     134             90.5          246   96.1   0.023
   C                     14              9.5           10    3.9    
  *ADIPOQ* rs2241766:                                               
   T                     146             99.3          245   96.1   0.062
   G                     1               0.7           10    3.9    

Nonagenarians and centenarians {#sec3.3}
------------------------------

Although there were significant differences in the distribution of genotypes between nonagenarians and centenarians in *FOXO3A* rs13217795 and *FOXO3A* rs2764264, the small number of observations among genotypes cannot lead to certain conclusions ([Table VIII](#t0008){ref-type="table"}). However, when testing by allele, the *T* allele was significantly more frequent in the nonagenarians than the centenarians in both *FOXO3A* rs13217795 and *FOXO3A* rs2764264 (64.4 vs. 44.1%, *p* = 0.018, 69.7 vs. 50.0%, *p* = 0.017, respectively; [Table IX](#t0009){ref-type="table"}).

###### 

Genotype frequencies in the study group according to age

  Genotypes              Study group   *P*-value               
  ---------------------- ------------- ----------- ---- ------ -------
  *TERT* rs2736098:                                            
   AA                    23            9.6         0    0.0    0.164
   GA                    99            41.3        5    29.4   
   GG                    118           49.2        12   70.6   
  *IGFBP3* rs2854744:                                          
   AA                    70            29.5        7    41.2   0.597
   AC                    120           50.6        7    41.2   
   CC                    47            19.8        3    17.6   
  *FOXO3A* rs13217795:                                         
   CC                    30            12.6        3    17.6   0.014
   CT                    110           46.0        13   76.5   
   TT                    99            41.4        1    5.9    
  *FOXO3A* rs2764264:                                          
   TT                    103           43.1        1    5.9    0.010
   CT                    127           53.1        15   88.2   
   CC                    9             3.8         1    5.9    
  *ADIPOQ* rs2241766:                                          
   TT                    163           68.5        13   76.5   0.894
   TG                    65            27.3        4    23.5   
   GG                    10            4.2         0    0.0    

###### 

Allele frequencies in the study group according to age

  Alleles                Study group   *P*-value               
  ---------------------- ------------- ----------- ---- ------ -------
  *TERT* rs2736095:                                            
   A                     145           30.2        5    14.7   0.055
   G                     335           69.8        29   85.3   
  *IGFBP3* rs2854744:                                          
   A                     260           54.9        21   61.8   0.434
   C                     214           45.1        13   38.2   
  *FOXO3A* rs13217795:                                         
   C                     170           35.6        19   55.9   0.018
   T                     308           64.4        15   44.1   
  *FOXO3A* rs2764264:                                          
   T                     333           69.7        17   50.0   0.017
   C                     145           30.3        17   50.0   
  *ADIPOQ* rs2241766:                                          
   T                     391           82.1        30   88.2   0.366
   G                     85            17.9        4    11.8   

Discussion {#sec4}
==========

We studied 5 SNPs in 4 candidate genes in pathways related to lipoprotein and glucose metabolism as well as to telomere length, given the fact that both pathways are closely related to ageing/longevity. We found that the frequency of the *C* allele of *FOXO3A*; rs2764264 was lower in the study group than in the control group and that the *T* allele was more frequent in nonagenarians compared with centenarians of both *FOXO3A* gene variants (rs13217795 and rs2764264). Furthermore, genotypic and allele frequencies did not differ between the 2 groups according to gender, although, in men, the frequency of *TT* genotype of *FOXO3A*; rs2764264 was higher in the study group than the control group.

Therefore, the present study demonstrated that, among the 4 candidate genes, only one gene (i.e. *FOXO3A*) may have a potential influence on human longevity.

Various studies have reported significant inter-individual variation in telomere length and telomerase activity in healthy individuals of the same age \[[@cit0017], [@cit0018]\]. It has been observed that individuals with shorter telomeres are at higher risk of diseases that shorten lifespan such as cancers (e.g. lung cancer) \[[@cit0019]\]. With regard to age, we found no differences in the frequency of *TERT* gene polymorphism. In accordance with our finding, Liu *et al.* also reported no influence of *TERT* gene polymorphism on human lifespan in Han Chinese peri-centenarians \[[@cit0020]\]. Bressler *et al.* \[[@cit0018]\] evaluated the association between six *TERT* polymorphisms with CVD and mortality in White (*n* = 8,907) and African-American participants (*n* = 3,022) in the Atherosclerosis Risk in Communities (ARIC) study with no history of CVD at baseline. They reported that 2 polymorphisms of the *TERT* gene (i.e. rs2853668 and rs2736122) were associated with CVD events (i.e. CHD and stroke) in African-Americans but not in Whites, suggesting inter-individual variation \[[@cit0018]\]. No associations with mortality were found in either racial group. However, Liu *et al.* \[[@cit0020]\] and Bressler *et al.* \[[@cit0018]\] evaluated different TERT gene polymorphisms from the one in our present study. The polymorphism evaluated by us (i.e. rs2736098A) has been associated with an increased risk of cancer as reported in a recent meta-analysis by Li *et al.* \[[@cit0019]\]; this association was more significant in Asians \[[@cit0019]\].

Roszkowska-Gancarz *et al.* found that serum adiponectin concentrations in female centenarians may be related to extreme longevity \[[@cit0021]\] and that adiponectin levels are modified by *ADIPOQ* gene polymorphism. Khabour *et al.* \[[@cit0022]\] found no difference between *ADIPOQ* gene polymorphisms (rs266729, rs2241766 and rs1501299) and longevity phenotype in a Jordanian population. Guzman-Ornelas *et al*. \[[@cit0023]\] evaluated the same gene polymorphism (rs2241766) as the one we studied, and did not observe any relationship between this polymorphism and adiponectin levels in Mexican-Mestizo individuals. In our study, we also found no difference in *ADIPOQ*; rs2241766 gene polymorphism frequency between the 2 studied groups. In contrast, Atzmon *et al.* \[[@cit0024]\] reported that over-representation of 2 common variants in the *ADIPOQ* gene (rs17300539 and a single base pair insertion/deletion polymorphism 2019 bp downstream of the ATG start codon in the 3\' untranslated region called as SNP+2019) may promote increased lifespan through the regulation of adiponectin production and/or secretion. With regard to CVD, which may shorten human life span, Kanu *et al*. \[[@cit0025]\] reported that variations in the *ADIPOQ* gene may either protect against CHD (i.e. rs2082940T allele) or be associated with CHD risk (i.e. rs3774261G allele) in a Northeast Han Chinese population (*n* = 1514). Furthermore, a recent meta-analysis found no association between the T45G polymorphism of the adiponectin gene and nonalcoholic fatty liver disease (NAFLD) \[[@cit0026]\]. It should be noted that NAFLD and its advanced form (i.e. nonalcoholic steatohepatitis, NASH) have been linked to increased liver and CVD morbidity and mortality \[[@cit0027], [@cit0028]\].

In a genome-wide association study of 10,280 middle-aged and older individuals, Kaplan *et al*. \[[@cit0029]\] confirmed a known association of the *IGFBP3* gene with IGFBP-3 levels and a borderline significant association between IGF-I concentration and *FOXO3*; rs2153960 and longevity. Similarly, He *et al.* \[[@cit0030]--[@cit0032]\] reported an association of *IGFBP3*; rs11977526 gene polymorphism with longevity phenotype in a Chinese cohort, which was different from our studied polymorphism (rs2854744). Deal *et al.* \[[@cit0031]\] found in 478 men from the Physicians' Health Study that the A allele had higher promoter activity at the --202 locus compared with the C allele of *IGFBP3* gene polymorphism, which is consistent with the relationship observed between genotype and circulating IGFBP-3.

Willcox *et al.* \[[@cit0012]\] first observed the association of *FOXO3A*; rs2802292 gene polymorphisms with longevity in 213 male Americans of Japanese ancestry aged \> 95 years old. This association was confirmed in Italian, American, Chinese and German populations \[[@cit0009]--[@cit0012]\].

Soerensen *et al*. \[[@cit0032]\] investigated fifteen *FOXO3A* gene polymorphisms in 1,088 oldest old Danes (age: 92--93) and found further evidence for the role of *FOXO3A* as a longevity candidate gene from younger ages to old age, but not during old age. In the same cohort, they also evaluated the association of the *FOXO3A* gene with aging-related phenotypes known to predict survival (i.e. cognitive function, self-reported health, hand grip strength and activity of daily living) in the oldest old and found that *FOXO3A* variations were related to bone fracture risk and activity of daily living \[[@cit0033]\]. Furthermore, Flachsbart *et al.* \[[@cit0010]\] studied 16 known *FOXO3A* SNPs in 1,762 German centenarians/nonagenarians and younger controls and observed that the allele and genotype frequencies for the nonagenarians were generally in the middle between those for the younger controls and for the centenarians, supporting the reported increase in allele and genotype frequencies with age. Furthermore, after correcting for multiple testing, some SNPs (rs3800231, rs9400239, and rs479744) remained significant, including rs13217795 and rs2764264, for men separately. Unfortunately, there is no overlap with our polymorphisms tested. With regard to men, we also found that the frequency of *TT* genotype of *FOXO3A*; rs2764264 was higher in the study group than the control group. Additionally, in the present study, we found that the *C* allele of rs2764264 of the *FOXO3A* gene was significantly lower in the study group than the control group. Similarly, Flachsbart *et al.* \[[@cit0010]\] reported that no *FOXO3A* SNPs correlated with longevity in centenarians compared with controls except for rs2764264. In the present study, among the oldest old (i.e. nonagenarians and centenarians), we found that the T allele was significantly more frequent in nonagenarians than centenarians for both variants of the *FOXO3A* gene.

FOXO3A is part of the insulin/IGF-1 signaling pathway, one of the key candidate pathways of longevity \[[@cit0034]\], and regulates the expression of several genes involved in a broad range of biological processes such as apoptosis, cell cycle transition, DNA repair, oxidative stress, cell differentiation and glucose metabolism \[[@cit0035]\]. Several animal studies have confirmed the positive role of the FOXO family in longevity. For example, lack of FOXO in *Drosophila melanogaster* increases sensitivity to oxidative stress \[[@cit0036]\], whereas its overexpression in *Drosophila* fat body was reported to reduce fecundity and increase lifespan in females (but not in males) \[[@cit0037]\]. *FOXO3* knockout female mice exhibited early depletion of functional ovarian follicles, oocyte death and infertility \[[@cit0038]\]. Furthermore, B cell localization and development, Ig levels and hematopoietic stem cell maintenance were affected in FOXO3 knockout mice \[[@cit0039], [@cit0040]\]. Limited studies in humans evaluated the relationship between *FOXO3A* gene polymorphisms and ageing-related phenotypes in the oldest old. Kuningas *et al.* \[[@cit0041]\] observed an increased risk of stroke and Pawlikowska *et al.* \[[@cit0042]\] found that rs4946935 was associated with death caused by cancer. Therefore, the *FOXO3A* gene may be considered as the second consistently confirmed longevity-associated gene in addition to the apolipoprotein E gene (*APOE*) according to current evidence in several study populations \[[@cit0009], [@cit0011], [@cit0012], [@cit0042]--[@cit0044]\].

Genetic studies on human longevity present a variety of limitations mainly due to the difficulty in enrolling a considerable number of oldest old and the non-existence of individuals born at the same time as centenarians but with different lifespan duration. Although there are data identifying some genes as related to longevity and ageing, more evidence is needed. In addition, epigenetics linked to diet or other environmental/lifestyle factors (such as smoking, physical activity and emotional stress) may play a role in longevity attainment \[[@cit0045]--[@cit0047]\].

The present study has the limitations and concerns of bias introduced by differences in characteristics of cases and controls due to its case-control study design. Furthermore, no environmental factors (e.g. smoking, exercise and others) were evaluated. There is only a small number of centenarians compared with nonagenarians, and the results might be exaggerated. However, our study has some strengths as the participants were carefully selected in accordance with race, age and family history, which were well documented.

In conclusion, there are differences in both studied *FOXO3A* gene polymorphisms according to survival status. Particularly, the individuals \> 90 years (i.e. the study group) had half of the *C* alleles compared with younger individuals \< 80 years (i.e. the control group). Furthermore, the centenarians less frequently had the T allele of both *FOXO3A* gene polymorphisms compared with the nonagenarians. No differences were found between the 2 groups with regard to *TERT*, *IGFBP3* and *ADIPOQ* gene polymorphisms. Therefore, it seems that some polymorphisms may be significant in prolonging our lifespan. Understanding ageing at a molecular level could possibly help us in slowing this process and extend our lifespan. Nevertheless, confirmation in additional study populations is needed.
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